Palvella Therapeutics, Inc. (PVLA)

NASDAQ: PVLA · Real-Time Price · USD

46.83

+2.19 (4.91%)

Aug 14, 2025, 1:41 PM - Market open

Palvella Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Net Income	-28.38	-17.43	18.69	-27.55
Stock-Based Compensation	2.99	0.83	0.6	0.43
Other Operating Activities	6.51	5.96	-29.85	10.66
Change in Accounts Payable	2.97	2.24	-2.25	1.98
Change in Other Net Operating Assets	-4.78	-2.43	-0.9	-0.36
Operating Cash Flow	-20.34	-10.84	-13.7	-14.84
Long-Term Debt Issued	-	18.43	5	-
Net Debt Issued (Repaid)	8.43	18.43	5	-
Issuance of Common Stock	60.42	60	-	0.03
Other Financing Activities	7.49	8.66	-	-
Financing Cash Flow	76.34	87.09	5	9.57
Foreign Exchange Rate Adjustments	-0.11	0	-	-
Net Cash Flow	55.9	76.25	-8.7	-5.27
Levered Free Cash Flow	-15.73	-5.43	-9.96	-
Unlevered Free Cash Flow	-13.05	-2.74	-9.96	-
Change in Working Capital	-1.45	-0.19	-3.15	1.62

Updated Aug 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q